Rheumatoid arthritis vaccine(Immune Response Biopharma, Inc.)(Rheumatoid arthritis vaccine(Immune Response Biopharma, Inc.))

概要

基本信息

药物类型

治疗性疫苗

别名

RAVAX、Rheumatoid arthritis vaccine、Zyvac-RA

+ [12]

靶点-

作用机制

免疫刺激剂

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病

在研适应症

类风湿关节炎

非在研适应症-

原研机构

Immune Response Biopharma, Inc.

在研机构

Immune Response Biopharma, Inc.

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Rheumatoid arthritis vaccine(Immune Response Biopharma, Inc.) 相关的临床试验

CTRI/2021/11/037996 / Active, not recruiting临床4期

An active post-marketing surveillance study to evaluate the safety and immunogenicity of ZyVac TCV of M/s. Cadila Healthcare Limited in healthy subjects - NA

开始日期2021-11-15

申办/合作机构-

CTRI/2021/09/036577 / Completed临床3期

A prospective, randomized, two-arm, parallel, active-controlled, multicentre, non-inferiority, phase III clinical trial to evaluate the immunogenicity and safety of ZyVac TCV of M/s Cadila Healthcare Limited compared to Typbar TCV of M/s Bharat Biotech International Limited in healthy adults aged 45 to 65 years - NA

开始日期2021-09-20

申办/合作机构-

100 项与 Rheumatoid arthritis vaccine(Immune Response Biopharma, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Rheumatoid arthritis vaccine(Immune Response Biopharma, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Rheumatoid arthritis vaccine(Immune Response Biopharma, Inc.) 相关的专利（医药）

登录后查看更多信息

3

项与 Rheumatoid arthritis vaccine(Immune Response Biopharma, Inc.) 相关的文献（医药）

2015-06-03·Expert Review of Vaccines2区 · 医学

Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis

2区 · 医学

Review

作者: Katalin Mikecz ; Roy E Carambula ; Tibor T Glant ; Daniel H Zimmerman ; Harold L Steiner ; Kenneth S Rosenthal ; Alison Finnegan

The current status of therapeutic vaccines for autoimmune diseases is reviewed with rheumatoid arthritis as the focus. Therapeutic vaccines for autoimmune diseases must regulate or subdue responses to common self-antigens. Ideally, such a vaccine would initiate an antigen-specific modulation of the T-cell immune response that drives the inflammatory disease. Appropriate animal models and types of T helper cells and signature cytokine responses that drive autoimmune disease are also discussed. Interpretation of these animal models must be done cautiously because the means of initiation, autoantigens, and even the signature cytokine and T helper cell (Th1 or Th17) responses that are involved in the disease may differ significantly from those in humans. We describe ligand epitope antigen presentation system vaccine modulation of T-cell autoimmune responses as a strategy for the design of therapeutic vaccines for rheumatoid arthritis, which may also be effective in other autoimmune conditions.

1998-11-01·Arthritis & Rheumatism

T cell receptor peptide vaccination in rheumatoid arthritis: A placebo-controlled trial using a combination of V?3, V?14, and V?17 Peptides

Article

作者: Heck, Louis W. ; Bathon, Joan ; Diveley, Jocelyn P. ; Matsumoto, Alan K. ; Richieri, Steven P. ; Matteson, Eric L. ; Calabrese, Leonard H. ; Carlo, Dennis J. ; Strand, Vibeke ; Brostoff, Steven W. ; Weyand, Cornelia M. ; Uramoto, Kristine M. ; Markenson, Joseph A. ; Morgan, Elizabeth E. ; Moreland, Larry W. ; Cash, Joseph M. ; Koopman, William J. ; Nardo, Christopher J. ; Fronek, Zdenka ; Adamson, Thomas C. III

OBJECTIVERestricted T cell receptor (TCR) gene usage has been demonstrated in animal models of autoimmune disease and has resulted in the successful use of TCR peptide therapy in animal studies. This clinical trial was undertaken to determine the safety and efficacy of a combination of Vbeta3, Vbeta14, and Vbeta17 TCR peptides in Freund's incomplete adjuvant (IFA) in patients with rheumatoid arthritis (RA).METHODSA double-blind, placebo-controlled, multicenter, phase II clinical trial was undertaken using IR501 therapeutic vaccine, which consists of a combination of 3 peptides derived from TCRs (Vbeta3, Vbeta14, and Vbeta17) in IFA. A total of 99 patients with active RA received either 90 microg (n = 31) or 300 microg (n = 35) of IR501 or IFA alone (n = 33) as a control. The study medication and placebo were administered as a single intramuscular injection (1 ml) at weeks 0, 4, 8, and 20.RESULTSTreatment with IR501 was safe and well tolerated. None of the patients discontinued the trial because of treatment-related adverse events. Efficacy was measured according to the American College of Rheumatology 20% improvement criteria. Using these criteria, patients in both IR501 dosage groups showed improvement in disease activity. In the most conservative analysis used to evaluate efficacy, an intent-to-treat analysis including all patients who enrolled, the 90-microg dosage group showed a statistically significant improvement compared with control patients at the 20-week time point after the third injection. Trends toward improvement were shown in both the 90-microg and the 300-microg dosage groups at week 24 after the fourth injection.CONCLUSIONIR501 therapeutic vaccine therapy was safe and well tolerated, immunogenic, and demonstrated clinical improvement in RA patients. Additional clinical trials are planned to confirm and extend these observations.

1970-03-01·Archives of Dermatology

Renal vasculitis and Bowen's disease

Article

作者: Yaffee, H. S.

To the Editor.— I would like to report a hitherto unrecorded observation; that of Bowen's disease and renal vasculitis. Report of a Case.— A 69-year-old white married woman was admitted to the Mount Auburn Hospital, Cambridge, Mass, in cardiovascular shock with severe pain in the right costovertebral angle, hematuria, nausea, and vomiting. Exploratory laparotomy revealed a perforation of a right renal artery for which the kidney was removed. The nephrectomy specimen (Fig 1) showed an acute necrotizing arteritis of the interlobular arteries of the lower pole between the hilus and the renal pelvis. Microscopically there was necrosis with fibrinoid changes and microaneurysm formation. There was scattered scarring of the renal parenchyma, an occasional sclerotic vessel, but no diffuse arteritis. The glomeruli were essentially normal. She had rheumatoid arthritis for many years with typical hand deformity. Two years prior to her admission she received injections of an unknown "arthritis vaccine." She

100 项与 Rheumatoid arthritis vaccine(Immune Response Biopharma, Inc.) 相关的药物交易

登录后查看更多信息